1. Home
  2. CRDL vs ANIX Comparison

CRDL vs ANIX Comparison

Compare CRDL & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.05

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.18

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDL
ANIX
Founded
2017
1982
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
104.0M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
CRDL
ANIX
Price
$1.05
$3.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$9.00
$9.00
AVG Volume (30 Days)
328.2K
235.2K
Earning Date
11-13-2025
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$2.28
52 Week High
$1.59
$5.46

Technical Indicators

Market Signals
Indicator
CRDL
ANIX
Relative Strength Index (RSI) 59.15 40.61
Support Level $0.94 $3.07
Resistance Level $1.03 $3.36
Average True Range (ATR) 0.05 0.17
MACD 0.00 0.04
Stochastic Oscillator 85.71 23.08

Price Performance

Historical Comparison
CRDL
ANIX

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Share on Social Networks: